Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far

Author(s): Vadiraj D. Kurdekar, Hemant R. Jadhav

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 15 , Issue 2 , 2015

Become EABM
Become Reviewer
Call for Editor


Rheumatoid Arthritis (RA) is an autoimmune disease characterized by persistent inflammation and joint damage. The main aim of RA treatment is to control the disease progress. Despite the success of biologicals like Adalimumab, Atlizumab, infliximab, etc. in treatment of RA, the high cost and associated immunological adverse effects have triggered discovery of small molecules targeting RA. This review describes the last 15 years of small molecular drug discovery in RA, focused mainly on preclinical and clinical studies.

Keywords: Janus kinase, peptidyl arginine deiminase, phosphoinositide 3-kinase, rheumatoid arthritis, TNFα-converting enzyme, Tyrosine kinase.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 05 March, 2015
Page: [123 - 144]
Pages: 22
DOI: 10.2174/1389557515666150101101850
Price: $65

Article Metrics

PDF: 45
PRC: 1